Medicine Matters diabetes

With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded.

What do the results of CVOTs mean for practicing clinicians? Medicine Matters contributor, Carol Wysham reviews the latest evidence and guidelines for reducing CV risk in patients with type 2 diabetes.

As 2016 draws to a close, our editorial board members reflect on the key advances in understanding and treating diabetes over the past year, and give their thoughts on the research to watch out for in 2017.

Jay Shubrook, Chair of the American Diabetes Association’s Primary Care Advisory Group, outlines what's new in 2017's ADA Standards of Care update. 

A process of shared and informed decision-making, facilitated by demonstration, helps ensure that the right delivery device is chosen and prescribed for persons who require insulin.

A call to action from editorial board member Lori Berard.

Editorial board member John Wilding outlines key moments from the 52nd annual meeting of the European Association for the Study of Diabetes in Munich, Germany.

Jay Shubrook explores why it is so important to include hypoglycemia assessment and management as part of your diabetes management plan.